Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma

Cancer Science

Volumn 105, Issue 7, 2014, Pages 883-889

  Kaku, Yoshiko ^a   Nagaya, Hisao ^a   Tsuchiya, Ayako ^a   Kanno, Takeshi ^a   Gotoh, Akinobu ^a   Tanaka, Akito ^a   Shimizu, Tadashi ^a   Nakao, Syuhei ^a   Tabata, Chiharu ^a   Nakano, Takashi ^a   Nishizaki, Tomoyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcl 2 family; HUHS1015; Malignant pleural mesothelioma; Synthetic anticancer compound

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HUHS 1015; MESSENGER RNA; NAFTOPIDIL; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL VIABILITY; DRUG EFFICACY; DRUG SYNTHESIS; FLOW CYTOMETRY; MESOTHELIOMA CELL LINE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BCL-2 FAMILY; HUHS1015; MALIGNANT PLEURAL MESOTHELIOMA; SYNTHETIC ANTICANCER COMPOUND;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; PLEURAL NEOPLASMS; PROPANOLAMINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 84904366125     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12429     Document Type: Article

References (12)

1. 1-adrenoceptor blocking. Anticancer Res 2013; 33: 887-94.
2. Kanno T, Tanaka A, Shimizu T, Nakano T, Nishizaki T. 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug. Pharmacology 2013; 91: 339-45.
3. Vanags DM, Pörn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271: 31075-85.
4. Pietra G, Mortarini R, Parmiani G, Anichini A. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res 2001; 61: 8218-26.
5. Blanco E, Ferrari M. Emerging nanotherapeutic strategies in breast cancer. Breast 2014; 23: 10-8.
6. Leamon CP, Lovejoy CD, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med 2013; 6: 113-25.
7. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013; 170: 365-72.
8. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013; 3: 259.
9. Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther 2013; 9: 1231-41.
10. Ma WW, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013; 19: 5572-9.
11. Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther 2013; 20: 1-7.
12. Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol 2012; 64: 1695-702.